return to news
  1. Lupin signs patent licence pact with Takeda for novel gastrointestinal drug in Indian market

Market News

Lupin signs patent licence pact with Takeda for novel gastrointestinal drug in Indian market

PTI.jpg

1 min read | Updated on September 18, 2024, 14:54 IST

Twitter Page
Linkedin Page
Whatsapp Page

SUMMARY

On Wednesday, Lupin Ltd announced that it has secured a non-exclusive license from Takeda to market Vonoprazan tablets in India under the name Lupivon, available in 10 mg and 20 mg, for treating various gastrointestinal disorders.

Stock list

Takeda has granted Lupin non-exclusive patent licensing rights to commercialise Vonoprazan in India

Takeda has granted Lupin non-exclusive patent licensing rights to commercialise Vonoprazan in India

Home-grown pharma major Lupin Ltd. on Wednesday said it has entered into a non-exclusive patent licence agreement with Takeda Pharmaceutical Company Ltd to commercialise Vonoprazan tablets, a novel gastrointestinal drug, in the Indian market.
Open FREE Demat Account within minutes!
Join now

Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialise Vonoprazan in India, the company said in a regulatory filing.

The drug will be marketed under the brand name Lupin's Lupivon and will be available in two strengths--10 mg and 20 mg, it added.

Lupin President India Region Formulations Rajeev Sibal said Vonoprazan is a novel treatment option for acid peptic disorders.

The pact with Takeda is "a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address unmet needs of our patients," he added.

In India, Vonoprazan is approved by the DCGI (Drugs Controller General of India) for treating reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of Helicobacter pylori eradication treatment, Lupin said in the filing.

SIP
Consistency beats timing.
promotion image

About The Author

PTI.jpg
Press Trust of India (PTI) is India's premier news agency.

Next Story